ClinicalTrials.gg
TerminatedNCT03316794Updated Dec 17, 2018

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

A Phase 1 interventional study of SC-005 in Breast Cancer, sponsored by AbbVie. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-17.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's title name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Strategic considerations

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Triple Negative Breast Neoplasms by AbbVie — 2 open to participants now, 4 under way, none of them phase 3. Triple Negative Breast Neoplasms · AbbVie.

Started
2018
the only one that year
Phase 1
8 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Triple Negative Breast Neoplasms by AbbVie, this one is the only one that started in 2018, is one of 8 in phase 1, and was the 6th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 443 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

2 of the 10 studies in Triple Negative Breast Neoplasms by AbbVie are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 330 Triple Negative Breast Neoplasms studies recruiting now, 230 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Triple Negative Breast Neoplasms by AbbVie, or all of them as a file.
02

Study summary

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Triple Negative Breast Cancer
  • Cancer
  • Breast Cancer
  • Maximum tolerated dose (MTD)
  • Pharmacokinetics
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 443 are open to participants now.

This study's enrollment of 2 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced TNBC that is , refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.

    • Advanced disease is defined as disease or locally advanced disease that is not amenable to surgery or radiotherapy with curative intent
    • TNBC is defined as:
  • \<1% staining by immunohistochemistry (IHC) for estrogen (ER) and progesterone (PR) receptors, 0 or 1+ IHC for human epidermal growth factor receptor 2 (), OR
  • Negative for HER2 amplification by in situ hybridization (ISH) for 2+ IHC disease.
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic, hepatic, and renal function.

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition including any suggested by Screening laboratory findings that, in the opinion of the Investigator or Sponsor, may place the subject at undue risk from the study.
  • Has abnormalities that make corrected (QTc) evaluation difficult (e.g., severe morphologic abnormalities).
  • Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known or to SC-005 or contained in the drug formulation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    SC-005

    SC-005 intravenous (IV) (various doses and dose regimens)

    Drug: SC-005

Interventions

  • DrugSC-005

    intravenous

07

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-limiting Toxicities (DLTs)

    DLTs graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.

    Time frame: Minimum 21 days

Secondary outcomes

  1. QTcF Change from Baseline

    QT interval measurement corrected by Fridericia's formula (QTcF)

    Time frame: Up to approximately 9 weeks

  2. Area Under the Plasma Concentration-time Curve (AUC)

    Area under the plasma concentration-time curve (AUC) of SC-005.

    Time frame: Up to approximately 9 weeks

  3. Clinical benefit rate (CBR)

    CBR is defined as the proportion of participants with an objective response or stable disease (CR+PR +SD).

    Time frame: Up to approximately 4 years

  4. Maximum plasma concentration observed (Cmax)

    Maximum plasma concentration observed (Cmax) of SC-005

    Time frame: Up to approximately 9 weeks

  5. Overall Survival (OS)

    OS is defined as the time from the participant's first dose date to death due to any cause.

    Time frame: Up to approximately 4 years

  6. Observed Plasma Concentrations at Trough

    Observed plasma concentrations at trough of SC-005.

    Time frame: Up to approximately 9 weeks

  7. Duration of Clinical Benefit (DOCB)

    DOCB is defined as the time from the participant's initial observation of clinical benefit (CR or PR or stable disease \[SD\]) to PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

  8. Objective Response Rate (ORR)Up to approximately 4 years

    Objective response rate is defined as the proportion of participants with complete response (CR) or partial response (PR) based on RECIST version 1.1.

    Time frame: Up to approximately 4 years

  9. Time of Cmax (Tmax)

    Time of Cmax (Tmax) of SC-005.

    Time frame: Up to approximately 9 weeks

  10. Progression Free Survival (PFS)

    PFS time is defined as the time from the participant's first dose of study drug (Day 1) to either the participant's disease progression or death due to any cause.

    Time frame: Up to approximately 4 years

  11. Duration of Response (DOR)

    DOR is defined as the time from the participants initial objective response (CR or PR) to disease progression (PD) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

08

Study locations

8 sites
  • University of Chicago /ID# 169231
    Chicago, Illinois 60637-1443, United States
  • Washington University School /ID# 169177
    Saint Louis, Missouri 63108, United States
  • Memorial Sloan Kettering /ID# 201016
    New York, New York 10065, United States
  • Gabrail Cancer Center Research /ID# 168756
    Canton, Ohio 44718, United States
  • Oklahoma University /ID# 200937
    Oklahoma City, Oklahoma 73104, United States
  • Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
    Nashville, Tennessee 37203, United States
  • Baylor University /ID# 169860
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center /ID# 169232
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Oct 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2017
First posted
Oct 20, 2017
StartActual
Jan 4, 2018
Primary completionActual
Oct 5, 2018
CompletionActual
Oct 5, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03316794
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Jan 4, 2018
Primary completion
Oct 5, 2018
Completion
Oct 5, 2018
Last update
Dec 17, 2018

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion